Company Encyclopedia
View More
name
Chemclin Diagnostics
688468.SH
Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such as hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A, hepatitis E, etc.; and detection of tumor markers, thyroid hormones, reproductive endocrine hormones, cardiac markers, and inflammation. The company was founded in 2007 and is headquartered in Beijing, China.
340.79 B
688468.SHMarket value -Rank by Market Cap -/-

Financial Score

21/11/2025 Update
C
Health Care SuppliesIndustry
Industry Ranking31/41
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE4.02%C
    • Profit Margin15.99%A
    • Gross Margin71.15%A
  • Growth ScoreE
    • Revenue YoY-20.40%E
    • Net Profit YoY-59.45%D
    • Total Assets YoY-3.64%D
    • Net Assets YoY0.51%C
  • Cash ScoreD
    • Cash Flow Margin625.50%C
    • OCF YoY-20.40%E
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreA
    • Gearing Ratio20.50%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Chemclin Diagnostics released its semi-annual performance, with a net profit attributable to the parent company of 24.34 million yuan, a year-on-year decrease of 68.24%

    According to the Zhitong Finance APP, Chemclin Diagnostics disclosed its semi-annual report for 2025. During the reporting period, the company achieved revenue of 165 million yuan, a year-on-year decrease of 27.03%; net profit attributable to the parent company was 24.34 million yuan, a year-on-year decrease of 68.24%; net profit excluding non-recurring gains and losses was 15.92 million yuan, a year-on-year decrease of 77.35%; basic earnings per share were 0.06 yuan

    Zhitong·
    SH
    688468
    -5.22%
    Zhitong·
    SH
    688468
    -5.22%

    Chemclin Diagnostics' net profit for the year 2024 is 127 million yuan, a year-on-year decrease of 13.83%

    According to the Zhitong Finance APP, Chemclin Diagnostics disclosed its performance report for the year 2024. The company achieved operating revenue of 436 million yuan, a decrease of 2.03% compared to the same period last year; the net profit attributable to the owners of the parent company was 127 million yuan, a decrease of 13.83% compared to the same period last year; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was 101 million yuan, a decrease of 16.97% compared to the same period last year; the basic earnings per share were 0.32 yuan

    Zhitong·
    SH
    688468
    -5.22%
    Zhitong·
    SH
    688468
    -5.22%

    Chemclin Diagnostics: Shanghai Peixi and its concerted parties have completed a reduction of 3% of their shares

    According to the Zhitong Finance APP, Chemclin Diagnostics announced that from November 4, 2024, to December 18, 2024, Shanghai Peixi and its concerted party HJ CAPITAL cumulatively reduced their holdings of the company's shares by 12.0332 million shares, accounting for 3% of the company's total share capital. This reduction plan has been completed

    Zhitong·
    SH
    688468
    -5.22%
    Zhitong·
    SH
    688468
    -5.22%

    Chemclin Diagnostics shareholders Hengqin Junlian Zhikang and its concerted parties have cumulatively reduced their holdings by 1.8%

    According to the Zhitong Finance APP, Chemclin Diagnostics announced that on December 16, 2024, the company received a notice from shareholders regarding the completion of the share reduction plan. From October 25, 2024, to December 16, 2024, Hengqin Junlian Zhikang and its concerted party LOYAL CLASS cumulatively reduced their holdings by 7.21994 million shares, accounting for 1.8% of the company's total share capital. This share reduction plan has been completed

    Zhitong·
    SH
    688468
    -5.22%
    Zhitong·
    SH
    688468
    -5.22%